Heparin Binding Protein as a Prognostic Biomarker of Sepsis Severity
NCT ID: NCT05610020
Last Updated: 2022-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2021-10-01
2022-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hepcidin: a Prognostic Marker of Morbidity and Mortality in Severe Sepsis?
NCT03682003
Serum Albumin Ratios Can Improve Sepsis Mortality Prediction
NCT06640504
Evaluation of the Heparin Binding Protein Levels in Sepsis
NCT02533011
CRP Versus PCT as Bio-markers for Sepsis and in Guiding Antibiotics in Critically Ill Patients
NCT04049565
The Early Coagulopathy for the Prognosis in Sepsis
NCT04582188
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients suffered from sepsis or septic shock (under the third international consensus definition of sepsis and septic shock)
Exclusion Criteria
* Any patient who is Neutropenic secondary to malignancy
* Patients who is taking immunosuppressive therapy
* Patients who is suffering fromHematological malignancy
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Omar Hamdy
Specialist intensive care medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Omar Hamdy
Minya, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FMASU M D 159/ 2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.